Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML
JCO Global Oncology · 2026
DOI: 10.1200/go-25-00443 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Gojiri Mawalankar und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, ACTREC, Tata Memorial Centre, Navi Mumbai, India. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
PURPOSE The 2022 European LeukemiaNet (ELN22) genetic risk stratification for AML makes critical changes, including removal of FLT3- internal tandem duplications (ITD) allelic ratio and inclusion of mutations in myelodysplasia-related (MR) genes and in-frame bZIP CEBPA mutations. We evaluated the applicability of ELN22 in a uniformly treated younger AML cohort and explored refinements to improve risk prediction. METHODS We retrospectively analyzed 473 adult patients with AML treated with intensive therapy. A combination of cytogenetics and next-generation sequencing was used to stratify patients into the ELN17 and ELN22 risk. In addition, we also evaluated leukemic stem cell (LSC) burden at diagnosis and postinduction measurable residual disease by multiparametric flow cytometry. RESULTS A total of 77 cases (16.3%) were reclassified from ELN17, primarily because of changes associated with FLT3 -ITD, CEBPA , and MR gene mutations. As per ELN22, 56.7% of patients were classified as favorable, 28.3% intermediate, and 15.0% adverse risk. ELN22 adverse-risk patients had significantly inferior overall survival and relapse-free survival compared with intermediate- and favorable-risk patients. High LSC burden at diagnosis, presence of WT1 mutations, and DNMT3A-FLT3 -ITD comutated NPM 1 dichotomized the ELN22 intermediate-risk group. CONCLUSION We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of WT1 mutation status, triple-mutated NPM1 , and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematopathology, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
- Homi Bhabha National Institute (HBNI), Mumbai, India.
- Department of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India.
- Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India.
ORCID-Profile: Vishram Terse, Dhanlaxmi Shetty, Nishant Jindal, Sumeet Mirgh, Alok Shetty, Sachin Punatar, Lingaraj Nayak, Hasmukh Jain, Bhausaheb Bagal, Manju Sengar, Navin Khattry, Sweta Rajpal, Gaurav Chatterjee, Prashant Tembhare, Papagudi G Subramanian, Nikhil Patkar
Zitieren
APA
Mawalankar, G., Achrekar, A., Biswas, S., Terse, V., Joshi, S., Ugale, P., Bhanshe, P., Chaudhary, S., Kusurkar, S., Shahin, S., Gawde, V., Shetty, D., Jindal, N., Mirgh, S., Shetty, A., Gokarn, A., Punatar, S., Nayak, L., Jain, H., …, & Patkar, N. (2026). Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML. JCO Global Oncology. https://doi.org/10.1200/go-25-00443
Vancouver
Mawalankar G, Achrekar A, Biswas S, Terse V, Joshi S, Ugale P, et al. Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML. JCO Global Oncology. 2026. doi:10.1200/go-25-00443
BibTeX
@article{Mawalankar2026,
author = {Mawalankar, Gojiri and Achrekar, Aarti and Biswas, Seema and Terse, Vishram and Joshi, Swapnali and Ugale, Priyanka and Bhanshe, Prasanna and Chaudhary, Shruti and Kusurkar, Saurabh and Shahin, Shadma and Gawde, Vaibhav and Shetty, Dhanlaxmi and Jindal, Nishant and Mirgh, Sumeet and Shetty, Alok and Gokarn, Anant and Punatar, Sachin and Nayak, Lingaraj and Jain, Hasmukh and Bagal, Bhausaheb and Sengar, Manju and Khattry, Navin and Rajpal, Sweta and Chatterjee, Gaurav and Tembhare, Prashant and Subramanian, Papagudi G and Patkar, Nikhil},
title = {Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML},
journal = {JCO Global Oncology},
year = {2026},
doi = {10.1200/go-25-00443}
}
EUVIMED